Ninth Circuit Reverses Pacira's EXPAREL Royalty Win, Reviving RDF Royalty on 200-Liter Process
PCRX sits 94% above its 52-week low of $18.8.
Summary
The Ninth Circuit reversed part of Pacira's 2025 court win over RDF, holding the company does owe royalties on EXPAREL made with its 200-liter process. The royalty was previously eliminated and Pacira had recovered $28.3 million in cash; the amount now at stake is not quantified.
Key Events · Legal and Risk Events · PCRX
-
Appeals Court Reverses Royalty Win
On November 6, 2026, the Ninth Circuit reversed the District Court in part, holding that Pacira owes royalties on EXPAREL manufactured using its 200-liter process and directing judgment for RDF on that claim.
-
Prior Recovery Was $28.3 Million
The April 2025 judgment had eliminated the low single-digit royalty and required RDF to repay $23.1 million in royalties paid under protest plus $5.2 million statutory interest; Pacira received the $28.3 million in cash in July 2025.
-
Interest Recalculation Remanded
The Ninth Circuit remanded for the District Court to recalculate the pre-judgment interest RDF owes Pacira on the 45-liter EXPAREL portion of the judgment, which was not disturbed.
-
Exposure Not Quantified
Pacira says it is evaluating its legal options, intends to defend its rights vigorously, and cannot predict the outcome — no dollar estimate of reinstated royalties or repayment was provided.
Analysis · PCRX · Life Sciences
Pacira had won outright in the District Court: the low single-digit EXPAREL royalty to RDF was eliminated and Pacira recovered $23.1 million of royalties paid under protest plus $5.2 million in statutory interest, a $28.3 million cash payment received in July 2025. That win is now reversed in part by the Ninth Circuit, which held that Pacira does owe royalties on EXPAREL made with its 200-liter process and ordered judgment for RDF on that claim. Only the 45-liter portion survives, and even that is remanded for recalculation of the pre-judgment interest RDF owes Pacira. The company says it is evaluating its legal options and cannot predict the outcome, so the size of the reinstated royalty and any repayment obligation are unquantified. That matters less for the near-term P&L than for the pending $36.50-per-share Viatris tender: a revived royalty obligation is a liability the acquirer inherits, and it lands alongside the merger litigation disclosed in the concurrent 14D-9/A.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PCRX was trading at $36.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $18.80 to $36.67. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.